Investor Alert: Pomerantz Law Firm Investigates Galectin Therapeutics Inc. (NASDAQ: GALT)
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is currently investigating claims on behalf of investors of Galectin Therapeutics Inc. (NASDAQ: GALT). This investigation aims to determine if Galectin and certain officers or directors may have engaged in securities fraud or other unlawful business practices. Investors seeking further information are encouraged to contact Danielle Peyton via email at newaction@pomlaw.com or by phone at 646-581-9980, ext. 7980.
Recent Developments Affecting GALT Stock Price
On December 19, 2025, Galectin released a press announcement detailing the U.S. Food and Drug Administration’s (FDA) response to its previously submitted Type C meeting request concerning the development of its investigational drug, belapectin, a galectin-3 inhibitor. The FDA has shifted from an in-person meeting to a written response, prompting Galectin to pursue a follow-up Type C meeting to finalize the remaining components of its upcoming clinical trial design.
This announcement led to a significant decline in Galectin’s stock price, with shares falling by $1.78, or 28.9%, to close at $4.38 on the same day.
Pomerantz LLP's Role in Protecting Investor Rights
Pomerantz LLP, with a robust presence in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as a leading firm in corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm has a rich history of fighting for the rights of victims against securities fraud and corporate misconduct.
- Founded over 85 years ago by Abraham L. Pomerantz.
- Specializes in recovering multimillion-dollar damages for class members.
- Continues to uphold the legacy of protecting investor rights.
Next Steps for Investors
Investors who have experienced losses related to their holdings in Galectin Therapeutics Inc. (NASDAQ: GALT) are advised to seek legal counsel to explore potential actions they may undertake. Pomerantz LLP is actively gathering information and preparing to represent the interests of those affected.
For further inquiries or to join the class action, please reach out to Danielle Peyton at Pomerantz LLP via email at dpeyton@pomlaw.com or call 646-581-9980, ext. 7980.
Attorney advertising. Prior results do not guarantee similar outcomes.